JP2016506413A - 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 - Google Patents

空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 Download PDF

Info

Publication number
JP2016506413A
JP2016506413A JP2015551113A JP2015551113A JP2016506413A JP 2016506413 A JP2016506413 A JP 2016506413A JP 2015551113 A JP2015551113 A JP 2015551113A JP 2015551113 A JP2015551113 A JP 2015551113A JP 2016506413 A JP2016506413 A JP 2016506413A
Authority
JP
Japan
Prior art keywords
days
cancer
months
recombinant interferon
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015551113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506413A5 (OSRAM
Inventor
グアンウェン・ウェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Superlab Far East Ltd
Original Assignee
Superlab Far East Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Superlab Far East Ltd filed Critical Superlab Far East Ltd
Publication of JP2016506413A publication Critical patent/JP2016506413A/ja
Publication of JP2016506413A5 publication Critical patent/JP2016506413A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
JP2015551113A 2013-01-07 2014-01-07 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 Pending JP2016506413A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361749570P 2013-01-07 2013-01-07
US61/749,570 2013-01-07
US201361779711P 2013-03-13 2013-03-13
US61/779,711 2013-03-13
PCT/CN2014/000019 WO2014106459A2 (en) 2013-01-07 2014-01-07 A method for treating tumor by using recombinant interferon with changed spatial configuration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019190263A Division JP2020023547A (ja) 2013-01-07 2019-10-17 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法

Publications (2)

Publication Number Publication Date
JP2016506413A true JP2016506413A (ja) 2016-03-03
JP2016506413A5 JP2016506413A5 (OSRAM) 2017-02-16

Family

ID=51062515

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015551117A Pending JP2016508987A (ja) 2013-01-07 2014-01-07 インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物
JP2015551113A Pending JP2016506413A (ja) 2013-01-07 2014-01-07 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法
JP2019190263A Pending JP2020023547A (ja) 2013-01-07 2019-10-17 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法
JP2020066723A Pending JP2020105223A (ja) 2013-01-07 2020-04-02 インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物
JP2021200049A Pending JP2022031331A (ja) 2013-01-07 2021-12-09 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015551117A Pending JP2016508987A (ja) 2013-01-07 2014-01-07 インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019190263A Pending JP2020023547A (ja) 2013-01-07 2019-10-17 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法
JP2020066723A Pending JP2020105223A (ja) 2013-01-07 2020-04-02 インターフェロンの経皮及び／又は経粘膜投薬による骨ガン、皮膚癌、皮下腫瘍、粘膜癌及び／又は粘膜下腫瘍を治療する方法と組成物
JP2021200049A Pending JP2022031331A (ja) 2013-01-07 2021-12-09 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法

Country Status (10)

Country Link
US (6) US20160022778A1 (OSRAM)
EP (3) EP3895725A3 (OSRAM)
JP (5) JP2016508987A (OSRAM)
KR (4) KR20150139824A (OSRAM)
CN (2) CN104902917A (OSRAM)
AU (2) AU2014204368B2 (OSRAM)
CA (2) CA2897312C (OSRAM)
HK (2) HK1214528A1 (OSRAM)
TW (3) TWI718086B (OSRAM)
WO (2) WO2014106459A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504340A (ja) * 2021-01-21 2024-01-31 シャーメン アモイトップ バイオテック カンパニー， リミテッド 癌の再発を予防する方法及び組合せ医薬

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
TWI728975B (zh) * 2015-05-12 2021-06-01 英屬維爾京群島商遠東超級實驗室有限公司 鑒定對腫瘤具有直接抑制作用的干擾素的方法及其用途
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CN108721603B (zh) * 2017-04-14 2020-11-13 中国医学科学院基础医学研究所 干扰素α-1a在制备用于治疗癌症的药物中的用途
KR101880015B1 (ko) * 2017-12-08 2018-07-19 아주대학교산학협력단 인터페론 감마를 유효성분으로 함유하는 신경섬유육종 예방 또는 치료용 조성물
CA3121000A1 (en) * 2018-11-27 2020-06-04 The Children's Hospital Of Philadelphia Compositions and methods for treating cancer
WO2020252453A1 (en) * 2019-06-14 2020-12-17 The Brigham And Women's Hospital, Inc. Membrane attack complexes and uses thereof
CN111658779A (zh) * 2020-06-22 2020-09-15 四川大学华西医院 治疗新型冠状病毒肺炎的联合用药物
AU2022210179A1 (en) * 2021-01-21 2023-09-07 Biosteed Gene Transformation Tech. Co., Ltd. Interferon-based cancer treatment method, and pharmaceutical combination
US11759434B2 (en) * 2022-02-03 2023-09-19 Sytheon Limited Methods and compositions for treating melanoma and non-melanoma skin cancers
CN114533706B (zh) * 2022-02-15 2022-10-14 深圳市利云德生物技术有限公司 一种用于防治呼吸道疾病的雾化吸入制剂及其应用
WO2024076973A1 (en) * 2022-10-04 2024-04-11 Brown University Compositions and methods of delivering large proteins
WO2024186193A1 (ko) * 2023-03-08 2024-09-12 인제대학교 산학협력단 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001333785A (ja) * 2000-03-22 2001-12-04 Toshiba Corp ＭｘＡタンパク質の多型遺伝子およびその使用
JP2007503812A (ja) * 2003-08-28 2007-03-01 ヒュイヤンテック（ユーエスエー），インク． 空間構造によるタンパク質の機能の調節
JP2008532995A (ja) * 2005-03-09 2008-08-21 ウェイ グアンウェン 組換え高効率複合インターフェロンの使用方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2005169A (en) * 1932-08-27 1935-06-18 Rowe Andrew Reed Casting metal ingots
US4672108A (en) 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4681930A (en) 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US4846782A (en) * 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
EP0940154B1 (en) 1991-07-02 2007-04-18 Nektar Therapeutics Device for delivering aerosolized medicaments
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
RO113214B1 (ro) 1992-10-19 1998-05-29 Dura Pharma Inc Inhalator de pulbere uscata
JP3549533B2 (ja) 1993-01-19 2004-08-04 グラクソ、グループ、リミテッド 装置
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
WO1995017901A1 (en) * 1993-12-29 1995-07-06 Matrix Pharmaceutical, Inc. Methods and compositions for the treatment of a host with a cellular proliferative disease
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
EP0861321B1 (en) 1995-10-13 2006-05-31 President And Fellows Of Harvard College Phosphopantetheinyl transferases and uses thereof
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
US5972331A (en) 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
ATE209053T1 (de) 1996-01-03 2001-12-15 Glaxo Group Ltd Inhaliervorrichtung
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
CN1062565C (zh) 1998-06-29 2001-02-28 深圳九先生物工程有限公司 重组人α型复合干扰素及其制备方法和用途
US6833256B1 (en) 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
IL155741A0 (en) 2000-11-03 2003-12-23 Pbl Biomedical Lab Interferons, uses and compositions related thereto
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
FR2823764B1 (fr) 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
CN1375502A (zh) 2001-10-25 2002-10-23 南京药科大学 聚乙二醇修饰重组人干扰素
AU2003211297B2 (en) 2002-02-19 2007-12-06 Hisamitsu Pharmaceutical Co., Inc. Percutaneous absorption type plaster
WO2004091571A2 (en) 2003-04-08 2004-10-28 New Jersey Institute Of Technology (Njit) Polymer coating/encapsulation of nanoparticles using a supercritical antisolvent process
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
DK1663110T3 (en) 2003-08-28 2014-03-24 Superlab Far East Ltd APPLICATIONS OF INTERFERONES WITH CHANGED SPACIAL STRUCTURE
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
MY141751A (en) * 2003-08-28 2010-06-30 Sichuan Biotechnology Res Ct Recombinant super-compound interferon
CN1910195A (zh) 2003-08-28 2007-02-07 辉阳科技美国公司 通过空间构象调节蛋白质功能
FR2862541B1 (fr) * 2003-11-21 2007-04-20 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
US20080102114A1 (en) * 2004-04-23 2008-05-01 Panduranga Rao Koritala Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents
CN1740197B (zh) 2004-08-26 2010-05-12 辉阳科技美国公司 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
AU2006255122B2 (en) 2005-06-03 2010-10-21 Ambrx, Inc. Improved human interferon molecules and their uses
WO2007065303A1 (en) 2005-12-09 2007-06-14 Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. Transdermal patch containing isosorbide dinitrate and bisoprolol
CN101500616A (zh) 2006-08-04 2009-08-05 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
US8095213B1 (en) 2007-05-31 2012-01-10 Purdue Pharma L.P. Transdermal patch
ES2336873B1 (es) * 2007-11-07 2011-01-24 Proyecto De Biomedicina Cima, S.L. Composicion farmaceutica para el tratamiento de cancer.
BRPI1014854A2 (pt) * 2009-03-30 2016-05-03 Cerulean Pharma Inc "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
ES2413255T3 (es) 2009-04-09 2013-07-16 Lga Biotecnologie Srl Determinación de la eficacia de 5-ASA en la prevención y/o el tratamiento de CRC mediante el análisis de la expresión génica
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
JP5946459B2 (ja) 2010-09-27 2016-07-06 ゼスタジェン， エス．アー．Ｚｅｓｔａｇｅｎ， Ｓ．Ａ． 腫瘍形成（ｎｅｏｐｌａｓｉａ）を治療するための組成物および方法
MX360254B (es) * 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
US20130184437A9 (en) 2011-06-08 2013-07-18 Guangwen Wei Design and use of new recombinant interferons with altered spatial configuration and three-dimensional structure
US10016484B2 (en) 2011-11-14 2018-07-10 Five Prime Therapeutics, Inc. Methods of treating lung cancer
US20130273527A1 (en) * 2012-04-13 2013-10-17 Superlab Far East Limited Method for inducing cell senescence by recombinant interferon with altered spatial configuration
CN104703620A (zh) * 2012-07-20 2015-06-10 拉筹伯大学 诊断和治疗方法
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
KR102230547B1 (ko) 2013-11-13 2021-03-22 수퍼랩 파 이스트 리미티드 종양에 대한 직접적 억제 효과를 갖는 인터페론을 결정하는 방법 및 그의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001333785A (ja) * 2000-03-22 2001-12-04 Toshiba Corp ＭｘＡタンパク質の多型遺伝子およびその使用
JP2007503812A (ja) * 2003-08-28 2007-03-01 ヒュイヤンテック（ユーエスエー），インク． 空間構造によるタンパク質の機能の調節
JP2007516214A (ja) * 2003-08-28 2007-06-21 ヒュイヤンテック（ユーエスエー），インク． 空間構造が変えられるインターフェロン及びその応用
JP2008532995A (ja) * 2005-03-09 2008-08-21 ウェイ グアンウェン 組換え高効率複合インターフェロンの使用方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANTICANCER RES., vol. 14, JPN6018041932, 1994, pages 739 - 745, ISSN: 0004056990 *
ANTICANCER RES., vol. 16, JPN6018041940, 1996, pages 3855 - 3860, ISSN: 0003905755 *
SUPPORT.CARE CANCER, vol. 3, JPN6018041930, 1995, pages 78 - 80, ISSN: 0004056989 *
癌の臨床, vol. 32, JPN6018041935, 1986, pages 1451 - 1457, ISSN: 0004056991 *
肝臓, vol. 51, JPN6017043784, 2010, pages 565 - 571, ISSN: 0004056988 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504340A (ja) * 2021-01-21 2024-01-31 シャーメン アモイトップ バイオテック カンパニー， リミテッド 癌の再発を予防する方法及び組合せ医薬

Also Published As

Publication number Publication date
TW201427681A (zh) 2014-07-16
CN104994866A (zh) 2015-10-21
HK1216394A1 (zh) 2016-11-11
WO2014106459A8 (en) 2015-08-06
US20160022778A1 (en) 2016-01-28
US20180326012A1 (en) 2018-11-15
HK1217897A1 (en) 2017-01-27
KR20210069127A (ko) 2021-06-10
EP2941266A4 (en) 2016-09-07
AU2014204386A1 (en) 2015-08-27
CA2897312C (en) 2022-11-01
WO2014106492A2 (en) 2014-07-10
TW201427682A (zh) 2014-07-16
US10874716B2 (en) 2020-12-29
WO2014106492A3 (en) 2014-08-28
JP2020105223A (ja) 2020-07-09
KR20150139824A (ko) 2015-12-14
US20150352188A1 (en) 2015-12-10
EP2941264B1 (en) 2021-03-10
HK1217178A1 (en) 2016-12-30
AU2014204386B2 (en) 2018-07-26
AU2014204368A1 (en) 2015-08-20
WO2014106459A3 (en) 2014-09-04
TW201940189A (zh) 2019-10-16
US20210260164A1 (en) 2021-08-26
AU2014204368B2 (en) 2018-08-23
JP2022031331A (ja) 2022-02-18
HK1214528A1 (zh) 2016-07-29
EP2941266A2 (en) 2015-11-11
US12109250B2 (en) 2024-10-08
TWI718086B (zh) 2021-02-11
CA2897335A1 (en) 2014-07-10
JP2016508987A (ja) 2016-03-24
EP2941264A2 (en) 2015-11-11
EP2941264A4 (en) 2016-08-31
WO2014106459A2 (en) 2014-07-10
JP2020023547A (ja) 2020-02-13
EP3895725A3 (en) 2021-12-01
US20220339255A1 (en) 2022-10-27
CN104902917A (zh) 2015-09-09
KR20210077005A (ko) 2021-06-24
CA2897312A1 (en) 2014-07-10
TWI726291B (zh) 2021-05-01
KR20150103284A (ko) 2015-09-09
EP3895725A2 (en) 2021-10-20
EP2941266B1 (en) 2022-05-25
US20180344811A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
JP2022031331A (ja) 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法
TW201630597A (zh) 巴豆酯組成物及用於治療或減少血球細胞減少期間之用途
JP7682303B2 (ja) 進行固形腫瘍を治療する薬物の製造のためのミトキサントロン塩酸塩リポソームの用途
JP7376678B2 (ja) Ｍ１マクロファージを有効成分として含む癌細胞標的型薬物送達体及び光熱治療効果増進用組成物
US11110303B2 (en) Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
EP4232078A1 (en) Attenuated cancer cells and methods related thereto
CN102091062A (zh) 一种采取吸入给药紫杉醇治疗肺癌的方法
CN105233285B (zh) Epac直接或间接激动剂与溶瘤病毒的联合应用
HK1217178B (en) Recombinant interferon with changed spatial configuration for use in the treatment of malignant pleural effusion, malignant ascites, and/or malignant pericardial effusion
CN102961406B (zh) 一种蟾皮提取物干粉吸入剂
CN116585357A (zh) 一种僵蚕提取物的制备方法及其应用
WO2022068925A1 (zh) 动物非致病性细胞相关组分的应用和包含该组分的药物组合物
CN102961408B (zh) 一种蟾皮提取物干粉吸入剂
WO2022151335A2 (zh) 一种高压氧联合免疫药物用于肿瘤治疗的方法
TW200904404A (en) Methods and compositions for contributing to the treatment of cancers
EP1842921A1 (en) Recombined adenovirus p53 preparation for treating tumor
CN105854008A (zh) 含有乌司他丁的组合物在制备治疗口腔癌药物中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190617